EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Florent Baty, Sacha Rothschild, Martin Früh, Daniel Betticher, Cornelia Dröge, Richard Cathomas, Daniel Rauch, Oliver Gautschi, Lukas Bubendorf, Susanne Crowe, Francesco Zappa, Miklos Pless, Martin Brutsche, Swiss Group for Clinical Cancer Research
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2013
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1

Documents similaires